Ameriprise
SLN

Ameriprise’s Silence Therapeutics SLN Stock Holding History

Ameriprise’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.06M Buy
+370,052
New +$2.6M ﹤0.01% 2688
2025
Q1 		– Sell
-16,360
Closed -$113K – 4134
2024
Q4 		$113K Buy
+16,360
New +$211K ﹤0.01% 3943

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ameriprise's SLN Position: Q2 2026 in Review

Ameriprise opened a new position in Silence Therapeutics (SLN) in Q2 2026: 370,052 shares worth $4.06M. The stake represents ﹤0.01% of the portfolio and ranks #2688 among its holdings. This is a return to the name: Ameriprise previously reported a position in SLN as recently as Q4 2024.

Ameriprise first reported a position in SLN in Q4 2024 and has held it in 2 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Ameriprise held 370,052 shares of Silence Therapeutics worth $4.06M as of Q2 2026.
  • Silence Therapeutics was a new Ameriprise position in Q2 2026.
  • Silence Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2688 holding.
  • Ameriprise first reported a position in Silence Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.